Core Insights - Guangzhou Huaten Biomedical Technology Co., Ltd. has recently completed a B+ round of financing, raising several tens of millions of RMB [1] - The company, founded in 2019 and based in Guangzhou, focuses on research and experimental development [1] - The company has a registered capital of 15.019 million RMB and has completed its B+ round financing by 2026 [1] Company Overview - The legal representative of Guangzhou Huaten Biomedical Technology Co., Ltd. is Xie Shuilin [1] - The company has made investments in four other enterprises and holds 17 trademark registrations and 19 patents [1] - The company possesses 40 administrative licenses [1] Shareholders - The shareholders of Guangzhou Huaten Biomedical Technology Co., Ltd. include Xie Shuilin, Guangzhou Huaten Investment Consulting Partnership (Limited Partnership), Guangzhou Zhenhua Venture Capital Fund Partnership (Limited Partnership), Zhuhai Hengqin Zhineili Investment Partnership (Limited Partnership), and Guangzhou Yanghe Jiansheng Venture Capital Fund Partnership (Limited Partnership) [1]

Group 1 - The core viewpoint of the article is the launch of the "Shanghai Action Plan for Accelerating the Creation of an International First-Class Business Environment (2026)", which includes 26 tasks across four areas to enhance the business environment in Shanghai [1][5] - The plan focuses on improving efficient and convenient government services, fair and just market competition, a friendly industrial ecosystem, and a collaborative social governance environment [5] - The Shanghai Development and Reform Commission reported that over the past nine years, more than 1,300 specific measures have been implemented to address the pain points and bottlenecks faced by enterprises [7] Group 2 - The introduction of a "low-risk special item intelligent auxiliary approval model" by Shanghai Customs has reduced the average approval time by 70%, facilitating the rapid entry of special research items into domestic institutions [3] - As of December last year, Shanghai ranked at the global top level in 22 out of 59 evaluation points in the World Bank's survey of 119 economies, surpassing cities like Singapore, New York, London, and Hong Kong [9]

Group 1 - The newly released talent policy in Nanjing aims to attract approximately 10 top talents, 200 leading talents, and 2000 core talents annually, along with 300,000 new college graduates each year [1] - The policy is particularly beneficial for companies like Sequoia Gene, which focuses on attracting mid-level talents, aligning with the company's current recruitment strategy [1] - Nanjing's rich talent pool and innovative atmosphere were key factors for Sequoia Gene to establish its global R&D headquarters in the city two years ago, with a current R&D team of over 350 members [1] Group 2 - Nanjing has successfully attracted several major R&D projects, including BMW's global IT R&D center, which is the first of its kind in China, reinforcing the city's position as a digital hub for the company [2] - Other significant projects include Baidu's East China headquarters and large-scale R&D bases for Xiaomi and Alibaba, which collectively employ thousands of researchers [3] - The concentration of innovative projects and R&D centers is transforming Nanjing from a regional center into a key node in the global innovation network [3] Group 3 - The new talent policy is seen as a positive development for companies like Anke Immunology, which has expanded its workforce significantly since its establishment, now employing around 100 researchers [3] - The policy provides living subsidies for new employees, which is expected to help companies attract and retain talent, particularly young professionals [3][4] - The strategic decisions by various companies to establish R&D centers in Nanjing reflect a deeper layout based on the city's core competitive advantages [4]

来源：人民日报海外版 据新华社杭州1月2日电（记者黄筱）我国科学家成功构建了能够在单细胞分辨率下，同步实现细胞膜表 面标志物发现与靶向核酸适体探针获取的一体化平台——SPARK-seq。该技术为分子识别、原创靶点发 现及精准医学研究提供了全新工具，有望为众多因靶点不明而缺乏有效疗法的疾病开辟新的治疗途径。 由中国科学院杭州医学研究所谭蔚泓院士与吴芩研究员团队合作取得的这项研究成果，1月1日在国际学 术期刊《科学》上线。 细胞膜蛋白是药物作用的关键靶点，而核酸适体是一类能够高特异性、高亲和力结合靶标分子的寡核苷 酸。然而，传统的核酸适体筛选方法效率低、过程繁杂，且难以在生理相关环境下系统发现全新的疾病 标志物。 SPARK-seq平台的诞生解决了这一挑战。相较于传统方法，其筛选效率提升达百倍以上，并能高精度锁 定潜在的癌症标志物与治疗靶点。吴芩表示，"该平台在单细胞层面部署的'分子雷达'，能够大规模、 并行地精准识别细胞表面与疾病相关的靶标，并同步获取能特异性结合它的核酸适体探针。" SPARK-seq作为自主可控的原创性平台，为"无药可靶"疾病的靶点研究与治疗开发提供了全新范式，使 得科研与临床工作者能够基于 ...

Core Viewpoint - RNA-targeted small molecule drugs are emerging as a new frontier in the biopharmaceutical field, addressing the challenge of lacking precise tertiary structure information for most disease-related RNAs, which traditional computational methods rely on for predicting interactions with small molecules [2][5]. Group 1: SMRTnet Development - The research teams from Tsinghua University and Peking University developed a deep learning tool named SMRTnet, which predicts small molecule-RNA interactions without relying on RNA tertiary structures, thus expanding the range of targetable RNA [2][5]. - SMRTnet integrates two large language models, convolutional neural networks, and graph attention networks, utilizing only RNA sequence and secondary structure information to predict binding capabilities [5]. Group 2: Performance and Validation - SMRTnet demonstrated robust performance, achieving an average area under the receiver operating characteristic curve (auROC) of 0.830-0.844 in five-fold cross-validation, significantly outperforming existing tools [9]. - In bait evaluation tasks, SMRTnet's average ranking reached 92.6%, far exceeding four molecular docking tools (27.3%-46.6%) and two deep learning tools (16.0%-23.8%), indicating its superior ability to identify true binding molecules [9]. - The model's performance was notably affected when using predicted secondary structures instead of experimentally determined ones, highlighting the importance of accurate experimental data [10]. Group 3: Binding Site Prediction - SMRTnet can also identify small molecule binding sites on RNA, quantifying the contribution of each nucleotide to the predicted binding score using the Grad-CAM algorithm [12]. - The accuracy of binding site predictions was validated against experimentally determined sites, achieving an average auROC of 0.695-0.793 across multiple datasets [13]. - Out of 190 predicted small molecule-RNA interactions, 40 were experimentally validated as binding molecules, yielding an average validation rate of 21.1% [14]. Group 4: Case Study on MYC IRES - The research focused on MYC IRES, a target considered "undruggable," showing a positive correlation between predicted binding scores and experimental validation rates, with a validation rate of 28.6% for scores between 0.9-1.0 [16]. - Among 15 identified MYC IRES binders, the team highlighted IHT (Irinotecan Hydrochloride Trihydrate) for its favorable drug development characteristics [17]. - IHT was predicted to bind at a specific site on MYC IRES, and experimental validation confirmed the reliability of SMRTnet's predictions, demonstrating significant reductions in MYC mRNA and protein levels in HeLa cells [19]. Group 5: Future Prospects - SMRTnet represents a significant advancement in predicting small molecule-RNA interactions, overcoming traditional method limitations and broadening the scope of disease-related RNA targets [21]. - The accumulation of multi-omics data, including chemical-RNA interaction genomics and functional screening, is expected to enhance AI methods for predicting binding interactions and downstream biological effects, accelerating RNA-targeted drug development [21]. - The study illustrates the potential of AI-driven approaches in RNA-targeted small molecule therapy, with expectations for breakthrough advancements in the coming years as data quality and algorithm optimization improve [21].

研究团队在实验室讨论。（资料图） SPARK-seq作为自主可控的原创性平台，为"无药可靶"疾病的靶点研究与治疗开发提供了全新范式，使 得科研与临床工作者能够基于我国独特的临床资源，系统性地发现具有自主知识产权的新靶点与新工 具。未来，该技术有望推动形成一种"按图索骥"式的精准医疗新模式，快速为不同疾病匹配或定制治疗 分子，提升药物研发的效率和治疗方案的精准度。 细胞膜蛋白是药物作用的关键靶点，而核酸适体是一类能够高特异性、高亲和力结合靶标分子的寡核苷 酸。然而，传统的核酸适体筛选方法效率低、过程繁杂，且难以在生理相关环境下系统发现全新的疾病 标志物。 SPARK-seq平台的诞生解决了这一挑战。相较于传统方法，其筛选效率提升达百倍以上，并能高精度锁 定潜在的癌症标志物与治疗靶点。"我们研发SPARK-seq的初衷，是为了攻克像三阴性乳腺癌这类缺乏 明确治疗靶点的临床难题。"吴芩表示，"该平台在单细胞层面部署的'分子雷达'，能够大规模、并行地 精准识别细胞表面与疾病相关的靶标，并同步获取能特异性结合它的核酸适体探针。" 我国科学家成功构建了能够在单细胞分辨率下，同步实现细胞膜表面标志物发现与靶向核酸适体探针获 ...

Group 1 - The first "New Year Train" of the China-Europe Railway Express (Wuhan) has commenced its journey to Copenhagen, Denmark, marking a significant expansion of logistics networks to Northern Europe [2][3] - The train will travel through the Alashankou port, reaching Hamburg, Germany, with an estimated total transit time of 22 days [2] - During the New Year period, Hubei Port Han-Europe International is set to dispatch 27 round-trip trains, representing an 80% increase compared to the same period in 2025, enhancing international transport links between Hubei and Europe [7] Group 2 - Trade between Wuhan and Denmark is on the rise, with exports including transportation equipment, telecommunications products, and machinery, while imports consist mainly of dairy products, pharmaceuticals, and electronics [4] - Wuhan's automotive, optoelectronics, and biomedicine industries are collaborating with Copenhagen and Danish companies, with local enterprises like Dongfeng Motor and Lantu Automotive actively exploring the Northern European market [4] - Business delegations from Wuhan have frequently visited Copenhagen to foster economic exchanges, establishing connections with organizations such as the Danish Industry Association and Copenhagen Investment Promotion Agency [4]

Core Insights - The Chinese pharmaceutical industry is experiencing a significant breakthrough in innovative drug development, marking a decade of progress since 2015, which was recognized as the "Year of Chinese Innovative Drugs" [2] Group 1: Innovative Drug Development - The industry has seen over 110 domestically developed innovative drugs approved since the start of the 14th Five-Year Plan, with a market size reaching 100 billion yuan [8] - The number of innovative drugs in development accounts for over 20% of the global total, positioning China as the second-largest in new drug research and development [8] - Since 2018, a total of 265 innovative drugs have been approved in China, with 68 approved by November 2025 alone, which is more than six times the total for 2018 [9] Group 2: CAR-T Therapy and Chronic Kidney Disease - A new CAR-T therapy targeting kidney fibrosis has gained significant attention, highlighting the potential of innovative treatments to address chronic kidney disease (CKD), which affects approximately 788 million adults globally [3][4] - Traditional treatment options for kidney disease are limited, with high costs and reliance on dialysis for end-stage renal disease patients [4] - The CAR-T therapy aims to halt the progression of kidney disease by precisely targeting pathogenic cells, representing a shift from conventional treatment methods [5] Group 3: Policy Support and Market Expansion - Recent policies from the National Healthcare Security Administration and the National Health Commission have established a comprehensive support system for innovative drug development, enhancing market access and reimbursement mechanisms [7] - The dual-directory mechanism for including innovative drugs in basic medical insurance and commercial health insurance is expected to expand market opportunities for pharmaceutical companies [7] - The industry is entering a "window of opportunity" as major multinational pharmaceutical companies face patent expirations, creating demand for new products in oncology and other therapeutic areas [9] Group 4: International Market and Collaboration - By 2025, the total overseas licensing amount for Chinese innovative drugs is projected to exceed 100 billion USD, doubling from 2024 [10] - The collaboration model for overseas markets has evolved from simple licensing to joint development and commercialization, indicating a shift from a "seller" to a "partner" role for Chinese pharmaceutical companies [10] - This transformation signifies a transition from "following generics" to "source innovation," enhancing the global standing of Chinese innovative drugs [10]

Core Insights - The Chinese pharmaceutical industry is experiencing a significant breakthrough in innovative drug development, marking a decade of progress since 2015, which was recognized as the "Year of Chinese Innovative Drugs" [1][5] - Chronic Kidney Disease (CKD) is emerging as a global public health challenge, with approximately 788 million adults affected worldwide in 2023, highlighting the urgent need for new treatment options [2] - The CAR-T therapy shows promise in addressing kidney disease by targeting pathogenic cells, although initial trials faced challenges [3] Industry Developments - The Chinese government has implemented supportive policies for innovative drug development, including a comprehensive support system that enhances the entire drug development chain [3][4] - Since the "14th Five-Year Plan," over 110 innovative drugs have been approved in China, with the market size reaching 100 billion yuan, and the country now ranks second globally in new drug research and development [5][6] - The approval of 265 innovative drugs since 2018, with a significant increase in approvals in 2025, reflects the growing optimism in the industry regarding the drug development cycle [6] Market Opportunities - By 2030, many major multinational pharmaceutical companies will face patent expirations, creating opportunities for Chinese innovative drugs in areas like tumor immunotherapy and other therapeutic fields [6] - The overseas licensing of Chinese innovative drugs is projected to exceed 100 billion USD by 2025, indicating a shift from simple licensing to collaborative development models [7] - The transformation of Chinese pharmaceutical companies from "sellers" to "partners" in global markets signifies a strategic evolution towards original innovation [7] Future Challenges - The industry must transition from "fast following" to "best in class" and ultimately to "first in class" innovations, necessitating collaboration among research, policy, and capital [8] - Continued patience, courage, and wisdom are required to navigate the complexities of the evolving pharmaceutical landscape in China [8]

来源：新浪港股-好仓工作室 本次全球發售的聯席保薦人為摩根士丹利、中國國際金融香港證券有限公司及廣發證券（香港）金融控 股有限公司。英矽智能的股份預計將於2025年12月30日（星期二）上午九時正開始在聯交所買賣，股份 代號為3696，每手買賣單位為500股。 点击查看公告原文>> 声明：市场有风险，投资需谨慎。 本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验， 因此本文内容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联 系biz@staff.sina.com.cn。 英矽智能公布全球發售結果，最終發行價定為每股24.05港元。本次全球發售的發售股份數目為 94,690,500股，視乎超額配股權行使與否而定，其中香港發售股份數目為9,469,500股，國際發售股份數 目為85,221,000股。按發行價計算，所得款項總額約為22.77億港元，扣除估計應付上市開支2.52億港元 後，所得 ...